폐쇄형 약물 전달 장치(CSTD) 시장 - 세계 예측(2026-2032년)

The Closed System Transfer Devices Market is projected to grow by USD 4.23 billion at a CAGR of 13.31% by 2032.

Closed System Transfer Devices (CSTDs) are critical safeguards in modern oncology, hazardous drug compounding, and high-risk medication administration. These systems are designed to mechanically prevent environmental contaminants from entering drug vials and to limit the escape of hazardous drug vapors, aerosols, or droplets during preparation, transport, and administration. Their importance is reinforced by occupational health guidance from recognized agencies and professional bodies that identify antineoplastic and other hazardous drugs as a continuing exposure risk for pharmacists, nurses, technicians, and waste-handling personnel. As cancer care expands and cytotoxic agents, biologics, immunotherapies, and complex infusion therapies remain central to treatment protocols, healthcare facilities are strengthening containment practices across the medication-use process. Demand drivers include hazardous drug handling safety, oncology pharmacy automation, compounding safety, USP <800> compliance, NIOSH hazardous drug protection, closed drug-transfer technology, and cytotoxic drug exposure prevention. The executive focus is shifting from device procurement alone to evidence-based integration, staff competency, workflow validation, and compatibility with syringes, vials, infusion sets, elastomeric pumps, and electronic documentation systems.

Transformative Shifts in the Closed System Transfer Devices Landscape

The closed system transfer devices landscape is being reshaped by stricter hazardous drug handling expectations, greater scrutiny of occupational exposure, and a broader institutional commitment to healthcare worker safety. Regulatory and accreditation pressure has accelerated adoption of engineering controls, with facilities increasingly aligning CSTD use with biological safety cabinets, compounding aseptic containment isolators, personal protective equipment, medical surveillance programs, and hazardous drug waste protocols. A major shift is the move from isolated pharmacy use to end-to-end containment across receiving, storage, compounding, transport, bedside administration, spill response, and disposal. Device selection is also becoming more evidence-driven, with healthcare providers evaluating leak-tight performance, vapor containment, dry connection design, ease of priming, drug residual reduction, vial access integrity, needle-free compatibility, and usability under real clinical conditions. At the same time, oncology service decentralization, outpatient infusion growth, and home-based care models are increasing the need for consistent closed-transfer practices beyond traditional hospital cleanrooms. Sustainability is emerging as another factor, as facilities balance single-use contamination control with waste minimization, materials stewardship, and safe disposal of drug-contaminated components.

Cumulative Impact of Artificial Intelligence on CSTD Adoption and Safety

Artificial intelligence is influencing closed system transfer devices indirectly but materially through medication safety analytics, smart compounding workflows, exposure risk monitoring, and predictive quality management. AI-enabled pharmacy informatics can identify high-risk hazardous drug orders, flag mismatches between drug form and required containment workflow, and support standardized preparation protocols. In cleanroom and infusion operations, computer vision, barcode verification, and automated documentation can strengthen traceability by confirming vial identity, lot information, device connection steps, dose preparation sequence, and administration readiness. AI can also support staff training by analyzing simulation performance, detecting unsafe handling patterns, and personalizing competency refreshers for pharmacists, pharmacy technicians, and oncology nurses. From a risk-management perspective, machine learning can help correlate incident reports, spill logs, near misses, surface contamination testing, device complaints, and staffing patterns to identify exposure hotspots. While AI does not replace validated closed-system engineering controls, it can enhance compliance surveillance, reduce procedural variability, and improve hazardous drug handling governance when paired with robust cybersecurity, human oversight, and clinically validated workflows.

Key Regional Insights Across Asia-Pacific, Europe, North America, Latin America, Middle East, and Africa

Asia-Pacific is advancing closed system transfer device adoption as tertiary hospitals, cancer centers, and urban infusion networks modernize oncology pharmacy infrastructure, with Japan, Australia, South Korea, China, and India showing growing emphasis on hazardous drug safety, aseptic compounding, and healthcare worker protection. North America remains one of the most structured environments for CSTD utilization due to mature hazardous drug guidance, strong oncology infusion capacity, and institutional alignment with occupational exposure controls, particularly in hospital pharmacies and ambulatory cancer centers. Latin America is progressing through public and private oncology investment, with Brazil and Mexico emphasizing safer chemotherapy preparation while facing variability in procurement standards, staff training, and access to specialized compounding infrastructure. Europe demonstrates strong momentum through worker safety legislation, pharmacy practice standards, and cross-border emphasis on safe handling of cytotoxic drugs, with European health systems supporting harmonized containment expectations while national implementation levels differ. The Middle East is expanding CSTD relevance as advanced cancer hospitals, medical cities, and specialty infusion centers invest in international-quality pharmacy systems, particularly in Gulf health systems focused on accreditation and clinical excellence. Africa shows selective but important adoption, led by oncology referral centers, private hospitals, and internationally supported cancer programs, where the key priorities are affordable access, training, cleanroom capability, and standardized hazardous drug handling practices.

Key Group Insights Covering NATO, G7, BRICS, European Union, ASEAN, and GCC

ASEAN countries are increasingly prioritizing closed system transfer devices as oncology capacity expands in Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines, although adoption is shaped by differences in hospital accreditation, reimbursement, and pharmacy workforce development. The GCC is strengthening hazardous drug containment through major investments in specialty hospitals, cancer centers, and digitally enabled healthcare systems, with CSTD use supported by international accreditation models and centralized procurement practices. The European Union provides one of the most influential policy environments for occupational exposure reduction, with member states integrating cytotoxic drug safety into hospital pharmacy standards, worker protection rules, and environmental contamination controls. BRICS economies are strategically important because China, India, Brazil, Russia, and South Africa combine high cancer care needs with expanding domestic healthcare infrastructure, creating a practical need for scalable, cost-conscious closed-transfer solutions and training frameworks. G7 countries generally demonstrate mature clinical governance, advanced oncology services, and stronger institutional capacity for hazardous drug safety programs, making evidence generation, usability assessment, and workflow integration central to CSTD decisions. NATO countries, while not a healthcare market category in the traditional sense, include many advanced health systems and military medical services where occupational safety, standardized medical logistics, and readiness for hazardous medication handling can reinforce demand for closed drug-transfer protocols.

Key Country Insights for Closed System Transfer Devices Adoption and Implementation

The United States is a key reference point for closed system transfer device practices because hazardous drug handling is strongly influenced by occupational safety guidance, USP <800> implementation, oncology pharmacy standards, and extensive outpatient infusion networks. Canada emphasizes healthcare worker protection through provincial cancer agencies, hospital pharmacy guidance, and standardized safe handling protocols. Mexico is advancing adoption in major urban hospitals and oncology centers, supported by private healthcare growth and increasing attention to chemotherapy safety. Brazil is the leading Latin American setting for CSTD relevance due to its large oncology care base, hospital modernization, and expanding chemotherapy services, while implementation still depends on procurement consistency and staff training. The United Kingdom continues to focus on safe cytotoxic preparation, aseptic services, and pharmacy-led governance, and Germany benefits from rigorous hospital pharmacy standards, engineering control expectations, and strong oncology infrastructure. France, Italy, and Spain show sustained interest in exposure reduction, cleanroom quality, and infusion safety as cancer services remain major components of public healthcare delivery. Russia presents demand linked to centralized oncology modernization and hospital-based chemotherapy programs, with adoption influenced by regional healthcare investment differences. China is scaling oncology services across leading hospitals and provincial networks, increasing the need for standardized hazardous drug compounding and administration safeguards. India is expanding cancer care capacity through public and private hospitals, where CSTD use is gaining relevance alongside pharmacy training, affordability, and cleanroom infrastructure. Japan demonstrates strong compatibility with CSTD adoption due to advanced hospital pharmacy systems, aging-related oncology demand, and high procedural quality expectations. Australia supports hazardous drug safety through established oncology nursing and pharmacy standards, while South Korea combines advanced cancer treatment infrastructure with high interest in digital workflow controls and safe infusion practices.

Actionable Recommendations for Industry Leaders in Closed System Transfer Devices

Industry leaders should prioritize clinically validated CSTD performance, workflow compatibility, and staff adoption rather than treating devices as standalone products. Healthcare organizations benefit from mapping the full hazardous drug journey, from receiving and storage to compounding, transport, administration, spill response, and disposal, to identify points where closed-transfer protection is most critical. Procurement teams should assess device compatibility with commonly used vial sizes, syringes, infusion bags, administration sets, biologics, cytotoxic drugs, and automated compounding platforms. Training programs should include competency-based simulations for pharmacists, technicians, nurses, and waste handlers, supported by periodic audits and surface contamination monitoring where feasible. Manufacturers and suppliers should strengthen evidence packages around containment performance, usability, connection integrity, material compatibility, and reduction of drug residuals, while also addressing sustainability and packaging efficiency. Health systems should integrate CSTD protocols into electronic medication management, barcode verification, incident reporting, and quality dashboards. For global expansion, stakeholders should adapt market access strategies to regional regulatory maturity, oncology infrastructure, procurement models, and language-specific education requirements.

Research Methodology for Evidence-Based Closed System Transfer Devices Insights

The research approach for closed system transfer devices should combine primary and secondary methods to ensure verified, data-backed, and operationally relevant insights. Secondary research includes review of occupational safety guidance, hazardous drug lists, hospital pharmacy standards, oncology nursing protocols, regulatory documents, peer-reviewed contamination studies, medication safety publications, and cleanroom practice references. Primary research should include structured interviews with hospital pharmacists, oncology nurses, pharmacy technicians, infection prevention teams, procurement leaders, environmental health and safety officers, and clinical quality managers. Data triangulation is essential to compare regulatory expectations, real-world adoption barriers, device performance evidence, and workflow observations across regions and care settings. Qualitative assessment should examine usability, training burden, compatibility, spill prevention, administration efficiency, and staff confidence, while quantitative evidence can include contamination monitoring results, incident trends, competency completion rates, and compliance audit outcomes where available. The methodology should exclude speculative market sizing or forecasting and instead focus on evidence quality, regulatory alignment, clinical workflow relevance, occupational exposure reduction, and decision-making criteria for safe hazardous drug handling.

Conclusion on the Future of Closed System Transfer Devices

Closed system transfer devices are increasingly central to hazardous drug safety strategies as healthcare systems intensify protection for workers handling oncology and other high-risk medications. The strongest adoption drivers are not limited to regulation; they also include clinical risk reduction, cleanroom quality, infusion safety, staff confidence, and institutional accountability. Regional and country-level differences remain significant, with mature healthcare systems emphasizing compliance optimization and workflow integration, while emerging healthcare systems focus on access, affordability, training, and infrastructure readiness. Artificial intelligence, automation, and digital medication management will enhance the value of CSTDs by improving traceability, competency monitoring, and exposure-risk analytics, but validated engineering control performance will remain the foundation of safe handling. Industry leaders that align device design, evidence generation, training, sustainability, and digital integration will be best positioned to support safer hazardous drug preparation and administration across hospitals, cancer centers, and outpatient infusion settings.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Closed System Transfer Devices Market, by Product

• 7.1. Introduction
• 7.2. Bag & Line Access Devices
• 7.3. Syringe Safety Devices
• 7.4. Vial Access Devices

8. Closed System Transfer Devices Market, by Design Type

• 8.1. Introduction
• 8.2. Luer-Based Systems
• 8.3. Membrane-to-Membrane Systems

9. Closed System Transfer Devices Market, by Category

• 9.1. Introduction
• 9.2. Disposable
• 9.3. Reusable

10. Closed System Transfer Devices Market, by Locking Mechanism

• 10.1. Introduction
• 10.2. Click-To-Lock Design
• 10.3. Luer-Lock Design
• 10.4. Push-To-Turn Design

11. Closed System Transfer Devices Market, by Distribution Channel

• 11.1. Introduction
• 11.2. Offline
  • 11.2.1. Direct Sales
  • 11.2.2. Distributors & Wholesalers
• 11.3. Online

12. Closed System Transfer Devices Market, by End-User

• 12.1. Introduction
• 12.2. Homecare Settings
• 12.3. Hospitals & Clinics
• 12.4. Long-Term Care Facilities
• 12.5. Research Centers

13. Closed System Transfer Devices Market, by Region

• 13.1. Asia-Pacific
• 13.2. Europe
• 13.3. North America
• 13.4. Latin America
• 13.5. Africa
• 13.6. Middle East

14. Closed System Transfer Devices Market, by Group

• 14.1. NATO
• 14.2. G7
• 14.3. BRICS
• 14.4. European Union
• 14.5. ASEAN
• 14.6. GCC

15. Closed System Transfer Devices Market, by Country

• 15.1. China
• 15.2. United States
• 15.3. Japan
• 15.4. India
• 15.5. Germany
• 15.6. United Kingdom
• 15.7. Australia
• 15.8. France
• 15.9. South Korea
• 15.10. Italy
• 15.11. Canada
• 15.12. Russia
• 15.13. Brazil
• 15.14. Mexico
• 15.15. Spain

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. FPNV Positioning Matrix, 2025
• 16.3. Market Concentration Analysis, 2025
  • 16.3.1. Concentration Ratio (CR)
  • 16.3.2. Herfindahl Hirschman Index (HHI)
• 16.4. Recent Developments & Impact Analysis, 2025
• 16.5. Product Portfolio Analysis, 2025
• 16.6. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. B. Braun Melsungen AG
• 17.2. Baxter International Inc.
• 17.3. Becton, Dickinson and Company
• 17.4. Caragen Limited
• 17.5. Cardinal Health, Inc.
• 17.6. Codan Medical GmbH
• 17.7. Epic Medical
• 17.8. Equashield LLC
• 17.9. Fresenius Kabi
• 17.10. Grifols SA
• 17.11. ICU Medical, Inc.
• 17.12. JMS Co., Ltd.
• 17.13. Medline Industries, LP
• 17.14. Meissner Corporation
• 17.15. Paragon Care Limited
• 17.16. Sartorius AG
• 17.17. Simplivia Healthcare Ltd.
• 17.18. Terumo Corporation
• 17.19. Vygon (UK) Ltd
• 17.20. Yukon Medical, LLC
• 17.21. Zephyrus Innovations